Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA)
Authors' conclusion
These results provide evidence for the potential use of oral orforglipron to improve sleep-disordered breathing in adults with moderate to severe OSA and obesity or overweight.
Study context
- Population
- Adults with moderate to severe obstructive sleep apnea (OSA) and body mass index (BMI) of 27 or higher (obesity or overweight); trial 1 not receiving positive airway pressure treatment, trial 2 receiving positive airway pressure treatmentrandomized per trial · Trial 1 363 · Trial 2 349
- Comparison
- Orforglipron vs placebo
- Primary endpoint
- Change in apnea-hypopnea index (AHI, events/h) from baseline
- Follow-up
- Week 52
Methodological detailstwo 52-week trials, 66 sites in 9 countries
- Two 52-week trials
- 66 sites in 9 countries
Primary result
As reported in the abstract
ORFORGLIPRON (trial 1) vs PLACEBO (trial 1)
ORFORGLIPRON (trial 1)
−17.8
mean
PLACEBO (trial 1)
−4.5
mean
Estimate (95% CI)P value
Differencetrial 1
−13.2(−17.7 to −8.7)
P < 0.001ORFORGLIPRON (trial 2) vs PLACEBO (trial 2)
ORFORGLIPRON (trial 2)
−17.3
mean
PLACEBO (trial 2)
−5.3
mean
Estimate (95% CI)P value
Differencetrial 2
−12.0(−17.1 to −6.9)
P < 0.001Secondary outcomes
Key multiplicity-controlled secondary end points
- Of 7 key secondary end points, statistically significant, favoring orforglipron
- 6
Safety
Gastrointestinal adverse events (most commonly reported adverse events)
Original publication
Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA). JAMA. Published 9 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →